Treatment Experience of Palbociclib as a new Checkpoint Inhibitor
Sakurai, K.; Fujisaki, S.; Kubota, H.; Suzuki, Y.; Hara, Y.; Suzuki, S.; Adachi, K.; Tomita, R.; Enomoto, K.; Hirano, T.; Saga, R.; Makishima, M.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(10): 1498-1500
2018
ISSN/ISBN: 0385-0684 PMID: 30382057 Document Number: 696196
We encountered a case of multiple metastases from breast cancer. The patient was administered palbociclib, which was a new checkpoint inhibitor. The patient received various chemotherapies and endocrine therapies. We observed episode of care, a harm phenomenon, and tolerability. We did not recognize adverse events more severe than Grade 3 during the 6 weeks after initiating palbociclib therapy. Diagnostic imaging showed that the metastatic lesions maintained stable disease during the 6 weeks after initiating palbociclib therapy. This case suggested that palbociclib therapy is useful for patients with metastatic breast cancer.